• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Teva Pharmaceutical Industries

Teva Pharmaceutical Industries

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Research
  1. Teva Presents Gene Expression Analysis at Joint Actrims-Ectrims Meeting Demonstrating Copaxone® (Glatiramer Acetate Injection) Has a Complex Profile

    Teva Presents Gene Expression Analysis at Joint Actrims-Ectrims Meeting Demonstrating Copaxone® (Glatiramer Acetate Injection) Has a Complex Profile

  2. OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic ...

    OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer

  3. Teva Announces UK High Court Gives Positive Judgment in the Company’s Patent Case Against AstraZeneca

    Teva Announces UK High Court Gives Positive Judgment in the Company’s Patent Case Against AstraZeneca

  4. Research and Markets: Global Colon Carcinoma Therapeutics Pipeline Report 2014 - 5 Companies & 15 Drug Profiles

    Research and Markets: Global Colon Carcinoma Therapeutics Pipeline Report 2014 - 5 Companies & 15 Drug Profiles

  5. Research and Markets: Analyzing the Global Market for Active Pharmaceutical Ingredients - 2014

    Research and Markets: Analyzing the Global Market for Active Pharmaceutical Ingredients - 2014

  6. Ambit Announces Participation At Baird 2014 Health Care Conference

    Ambit Announces Participation At Baird 2014 Health Care Conference

  7. Research and Markets: Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical

    Research and Markets: Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical

  8. CVS Health Research Institute Study is First to Show Improved Medication Adherence and Health Outcomes for Generic Statins

    CVS Health Research Institute Study is First to Show Improved Medication Adherence and Health Outcomes for Generic Statins

  9. DEA restricts narcotic pain-drug prescriptions

    DEA restricts narcotic pain-drug prescriptions

  10. Fitch Affirms Amgen's IDR at 'BBB'; Outlook Remains Negative

    Fitch Affirms Amgen's IDR at 'BBB'; Outlook Remains Negative

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.